ALIVUSNSEQ2 FY24October 20, 2023

Alivus Life Sciences Limited

2,240words
1turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
ctober 20, 2023 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Plot No. C/1, G Block, To, The Manager – Listing, Natio
16.9%
d CDMO business bolsters our confidence of delivering growth in FY24” (I N ₹ M I LLI O N S ) 5,954 16.9% REVENUE YoY 2.9% QoQ • GLS registered a revenue from operations of ₹ 5,954 Mn for Q2FY24, record
2.9%
ters our confidence of delivering growth in FY24” (I N ₹ M I LLI O N S ) 5,954 16.9% REVENUE YoY 2.9% QoQ • GLS registered a revenue from operations of ₹ 5,954 Mn for Q2FY24, recording a strong grow
₹ 5,954
₹ M I LLI O N S ) 5,954 16.9% REVENUE YoY 2.9% QoQ • GLS registered a revenue from operations of ₹ 5,954 Mn for Q2FY24, recording a strong growth of 16.9% YoY and 2.9% QoQ (I N ₹ M I LLI O N S ) 1,725 1
12.2%
Mn for Q2FY24, recording a strong growth of 16.9% YoY and 2.9% QoQ (I N ₹ M I LLI O N S ) 1,725 12.2% EBITDA YoY (11.5%) QoQ (I N ₹ MI LLI O N S ) 1,187 11.1% PAT YoY (12.3%) QoQ • Gross Margins
11.5%
rding a strong growth of 16.9% YoY and 2.9% QoQ (I N ₹ M I LLI O N S ) 1,725 12.2% EBITDA YoY (11.5%) QoQ (I N ₹ MI LLI O N S ) 1,187 11.1% PAT YoY (12.3%) QoQ • Gross Margins improved in Q2FY24 t
11.1%
2.9% QoQ (I N ₹ M I LLI O N S ) 1,725 12.2% EBITDA YoY (11.5%) QoQ (I N ₹ MI LLI O N S ) 1,187 11.1% PAT YoY (12.3%) QoQ • Gross Margins improved in Q2FY24 trending at 54.1%, up 120 bps YoY; EBITDA
12.3%
M I LLI O N S ) 1,725 12.2% EBITDA YoY (11.5%) QoQ (I N ₹ MI LLI O N S ) 1,187 11.1% PAT YoY (12.3%) QoQ • Gross Margins improved in Q2FY24 trending at 54.1%, up 120 bps YoY; EBITDA margins at 29.0
54.1%
₹ MI LLI O N S ) 1,187 11.1% PAT YoY (12.3%) QoQ • Gross Margins improved in Q2FY24 trending at 54.1%, up 120 bps YoY; EBITDA margins at 29.0% down 120 bps YoY; driven by better gross margin and highe
120 bps
O N S ) 1,187 11.1% PAT YoY (12.3%) QoQ • Gross Margins improved in Q2FY24 trending at 54.1%, up 120 bps YoY; EBITDA margins at 29.0% down 120 bps YoY; driven by better gross margin and higher employee e
29.0%
2.3%) QoQ • Gross Margins improved in Q2FY24 trending at 54.1%, up 120 bps YoY; EBITDA margins at 29.0% down 120 bps YoY; driven by better gross margin and higher employee expense • Revenue from Generic
Rs. 5,428
driven by better gross margin and higher employee expense • Revenue from Generic API business was Rs. 5,428 Mn, up 19.7% YoY whereas CDMO business revenue was Rs. 253 Mn, down 18.1% YoY • Generated strong
Speaking time
REGISTERED OFFICE
1
Advertisement
Opening remarks
REGISTERED OFFICE
T: 91 22 68297979 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. CIN: U74900PN2011PLC139963 Website: www.glenmarklifesciences.com 19
Advertisement
← All transcriptsALIVUS stock page →